Lipum 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ola Sandborgh

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.2%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3.4yrs

최근 관리 업데이트

Recent updates

CEO

Ola Sandborgh (58 yo)

less than a year

테뉴어

Mr. Ola Sandborgh serves as CEO at Lipum AB (publ) since November 09, 2023. He has experience from the pharmaceutical industry where he has worked in leading roles in different commercial, innovation and b...

리더십 팀

이름	위치	테뉴어	보상	소유권
Olle Hernell	Co-Founder & Director	no data	SEK 347.00k	1.61% SEK 5.7m
Marina Norberg	Chief Financial Officer	3.8yrs	SEK 716.76k	0.077% SEK 272.2k
Ola Sandborgh	Chief Executive Officer	less than a year	데이터 없음	0.18% SEK 626.2k
Susanne Lindquist	Co-Founder & Head of Research (CSO)	no data	데이터 없음	1.53% SEK 5.4m
Pernilla Abrahamsson	Chief Operating Officer	no data	데이터 없음	0.034% SEK 119.0k
Peter Hovstadius	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: LIPUM 의 관리팀은 경험 (평균 재직 기간 1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Olle Hernell	Co-Founder & Director	no data	SEK 347.00k	1.61% SEK 5.7m
Gustav Kihlstrom	Independent Chairman of the Board	3.4yrs	데이터 없음	데이터 없음
Björn Löwenadler	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Carl-Johan Spak	Independent Director	1.5yrs	데이터 없음	0.017% SEK 58.5k
Anders Fasth	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lennart Lundberg	Member of Scientific Advisory Board	3.3yrs	데이터 없음	데이터 없음
Asa Hansdotter	Independent Director	3.4yrs	데이터 없음	데이터 없음
Kristian Sandberg	Independent Director	4.7yrs	데이터 없음	데이터 없음
Rikard Holmdahl	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Solbritt Dahlqvist	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Asa Magnusson	Director	less than a year	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

69.5yo

평균 연령

경험이 풍부한 이사회: LIPUM 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.

Lipum 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Lipum AB (Publ) Welcomes Peter Hovstadius as Chief Medical Officer

High number of new directors

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

Lipum Elects Carl-Johan Spak as New Board Member

Recent updates

Lipum AB (publ) to Report Q3, 2024 Results on Oct 25, 2024

Lipum AB (publ) to Report Fiscal Year 2024 Results on Feb 26, 2025

New minor risk - Share price stability

Lipum AB (Publ) Welcomes Peter Hovstadius as Chief Medical Officer

New major risk - Financial position

High number of new directors

Lipum AB (publ) Completes Multiple Dose Part of the Phase I Clinical Study

Lipum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 79.714945 million.

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Forecast to breakeven in 2025

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) Reports Positive Interim Results from Clinical Phase 1 Study Showing that SOL-116 Reduces Plasma BSSL Levels in Healthy Subjects

Lipum AB (Publ) Receives Funding from Vinnova for an Eurostars Application

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

New major risk - Revenue and earnings growth

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Lipum Elects Carl-Johan Spak as New Board Member

Chief Executive Officer recently bought kr161k worth of stock

Lipum AB (publ) Announces the Nomination Committee for the 2023 Annual General Meeting

Chief Executive Officer recently bought kr157k worth of stock

Lipum AB (Publ) Has Initiated A Phase 1 Clinical Study with Its Drug Candidate Sol-116

Lipum AB (publ) announced that it has received SEK 38.999963 million in funding from Flerie Invest AB

Lipum AB (publ) Gets Approval to Start Phase 1 Clinical Trial with Drug Candidate Sol-116

Lipum AB (publ) Appoints Helena Bergström as Chief Medical Officer

Lipum Reports Completion of GLP Toxicology- and Safety Program on the Candidate Drug (SOL-116)

Chief Executive Officer recently bought kr195k worth of stock

Lipum AB (Publ) Reports Gmp Production of Sol-116 Successful

Lipum Recruits Fredrik Seijsing as Scientist

Lipum AB (publ) Initiates GMP-Production for Clinical Trials

Lipum Is At the Final Step Before Clinical Phase

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령